Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods
Date Issued
2017-09-01Publisher Version
10.1016/j.cct.2017.07.006Author(s)
McHugh, R. Kathryn
Votaw, Victoria R.
Barlow, David H.
Fitzmaurice, Garrett M.
Greenfield, Shelly F.
Weiss, Roger D.
Metadata
Show full item recordPermanent Link
https://hdl.handle.net/2144/39158Version
Accepted manuscript
Citation (published version)
R Kathryn McHugh, Victoria R Votaw, David H Barlow, Garrett M Fitzmaurice, Shelly F Greenfield, Roger D Weiss. 2017. "Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods." Contemporary Clinical Trials, Volume 60, pp. 105 - 112. https://doi.org/10.1016/j.cct.2017.07.006Abstract
Opioid use disorder is a highly disabling psychiatric disorder, and is associated with both significant functional disruption and risk for negative health outcomes such as infectious disease and fatal overdose. Even among those who receive evidence-based pharmacotherapy for opioid use disorder, many drop out of treatment or relapse, highlighting the importance of novel treatment strategies for this population. Over 60% of those with opioid use disorder also meet diagnostic criteria for an anxiety disorder; however, efficacious treatments for this common co-occurrence have not be established. This manuscript describes the rationale and methods for a behavioral treatment development study designed to develop and test an integrated cognitive-behavioral therapy for those with co-occurring opioid use disorder and anxiety disorders. The aims of the study are (1) to develop and pilot test a new manualized cognitive behavioral therapy for co-occurring opioid use disorder and anxiety disorders, (2) to test the efficacy of this treatment relative to an active comparison treatment that targets opioid use disorder alone, and (3) to investigate the role of stress reactivity in both prognosis and recovery from opioid use disorder and anxiety disorders. Our overarching aim is to investigate whether this new treatment improves both anxiety and opioid use disorder outcomes relative to standard treatment. Identifying optimal treatment strategies for this population are needed to improve outcomes among those with this highly disabling and life-threatening disorder.
Collections
Related items
Showing items related by title, author, creator and subject.
-
A latent class analysis of parental bipolar disorder: examining associations with offspring psychopathology
Freed, Rachel D.; Tompson, Martha C.; Otto, Michael W.; Nierenberg, Andrew A.; Henin, Aude (ELSEVIER IRELAND LTD, 2015-12-15)Bipolar disorder (BD) is highly heterogeneous, and course variations are associated with patient outcomes. This diagnostic complexity challenges identification of patients in greatest need of intervention. Additionally, ... -
Anger: the unrecognized emotion in emotional disorders
Cassiello-Robbins, Clair; Barlow, David H. (WILEY, 2016-03-01)Anger plays a prominent definitional role in some psychological disorders currently widely scattered across DSM‐5 categories (e.g., intermittent explosive disorder, borderline personality disorder). But the presence and ... -
Adolescent D-amphetamine treatment in a rodent model of ADHD: pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood
Jordan, Chloe J.; Taylor, Danielle M.; Dwoskin, Linda P.; Kantak, Kathleen M. (Elsevier, 2016-01-15)Attention-deficit/hyperactivity disorder (ADHD) is comorbid with cocaine abuse. Whereas initiating ADHD medication in childhood does not alter later cocaine abuse risk, initiating medication during adolescence may increase ...